Alpha Tau Medical (DRTS) stock: reverse DCF, insider buying and superinvestor holders

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Alpha Tau Medical's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from DRTS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation1

Profitability0

Financial health8

Key numbers

P/E (trailing)—

P/E (forward)0.00x

Price / free cash flow—

EV / EBITDA—

Price / sales0.00x

Price / book14.5x

Revenue growth—

Operating margin—

Net margin—

Return on equity-55.3%

Dividend yield—

Debt / equity0.37x

Results from SEC filings

Fiscal years, from Alpha Tau Medical's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year	2021	2022	2023	2024	2025
Revenue	—	—	—	—	—
Net income	-$27M	-$34M	-$29M	-$32M	-$43M
Free cash flow	-$15M	-$25M	-$24M	-$22M	-$33M
EPS (diluted)	-$0.67	-$0.53	-$0.42	-$0.45	-$0.53
Operating margin	—	—	—	—	—

Superinvestors who own DRTS

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

Investor	Last quarter	Value	% of portfolio	Quarter
Andrew Redleaf Whitebox Advisors	Held	$401,253	0.01%	Q2 2026

Insider buying

Open-market purchases by Alpha Tau Medical's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of DRTS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when DRTS trades at or below it.

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share

Yearly return (IRR) at today's price

Growth implied by revenue and margins

15+ years of statements and quarters

Open DRTS in Investingly

Questions

Are Alpha Tau Medical insiders buying the stock?

No open-market insider purchases of DRTS in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Alpha Tau Medical?

1 of the superinvestors Investingly tracks hold DRTS in their latest 13F, including Andrew Redleaf.

Companies like Alpha Tau Medical

All Healthcare stocks · Biotechnology stocks · Stock lists

Ultragenyx (RARE)Market cap $1.4B Rapport Therapeutics, Inc. Common Stock (RAPP)Market cap $1.4B Inhibrx Biosciences, Inc. (INBX)Market cap $1.3B Damora Therapeutics, Inc. (DMRA)Market cap $1.3B AnaptysBio Inc (ANAB)Market cap $1.3B Ocular Therapeutix Inc (OCUL)Market cap $1.4B Ascentage Pharma Group International (AAPG)Market cap $1.3B Syndax Pharmaceuticals Inc (SNDX)Market cap $1.5B GH Research PLC (GHRS)Market cap $1.5B

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.